RenovoRx Reports Third Quarter 2024 Financial Results and …

2 days ago · Financial Highlights for Third Quarter ended September 30, 2024 (unaudited): Cash Position: Cash and cash equivalents as of September 30, 2024, were $9.6 million. R&D …

CouponFollow Extension

$9
OFF

RenovoRx Reports Third Quarter 2024 Financial Results And …

1 week from now

2 days ago · Financial Highlights for Third Quarter ended September 30, 2024 (unaudited): Cash Position: Cash and cash equivalents as of September 30, 2024, were $9.6 million. R&D …

renovorx.com

$9
OFF

RenovoRx Reports Third Quarter 2024 Financial Results And …

1 week from now

2 days ago · Financial Highlights for Third Quarter ended September 30, 2024 (unaudited): Cash Position: Cash and cash equivalents as of September 30, 2024, were $9.6 million.

businessinsider.com

$9
OFF

RenovoRx Reports Third Quarter 2024 Financial Results And …

1 week from now

2 days ago · RenovoRx reported Q3 2024 financial results with $9.6 million in cash as of September 30, sufficient to fund operations through next interim analysis of its Phase III …

stocktitan.net

$3
OFF

RenovoRx Reports Third Quarter 2023 Financial Results And …

1 week from now

Nov 14, 2023 · Financial Highlights for Third Quarter ended September 30, 2023: Cash Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million. R&D Expenses: …

renovorx.com

$13
OFF

Intel Reports Third-Quarter 2024 Financial Results

1 week from now

Oct 31, 2024 · Forecasting fourth-quarter 2024 revenue of $13.3 billion to $14.3 billion; expecting fourth-quarter GAAP EPS attributable to Intel of $(0.24); non-GAAP EPS attributable to Intel of …

intc.com

$1
OFF

Novavax Reports Third Quarter 2024 Financial Results And …

1 week from now

4 days ago · Ended the third quarter of 2024 with $1 billion in cash and receivables Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula …

prnewswire.com

$240
OFF

Immunome Reports Third Quarter 2024 Financial Results And …

1 week from now

2 days ago · Third Quarter 2024 Financial Results As of September 30, 2024, cash, cash equivalents and marketable securities totaled $240.1 million. Immunome’s current cash …

yahoo.com

$2
OFF

Advance Auto Parts Reports Third Quarter 2024 Results And …

1 week from now

2 days ago · Third Quarter 2024 Results (1,2,3,4) Third quarter 2024 net sales from continuing operations totaled $2.1 billion, compared with $2.2 billion in the third quarter of the prior year. …

advanceautoparts.com

$38
OFF

Novavax Reports Third Quarter 2024 Financial Results And …

1 week from now

Sep 30, 2024 · Product sales of $38 million for the third quarter 2024 related to primarily U.S. market commercial sales. Licensing, royalties and other revenue of $46 million in the third …

novavax.com

FAQs about RenovoRx Reports Third Quarter 2024 Financial Results and … Coupon?

What did renovorx do in the third quarter of 2024?

“We made significant progress in the third quarter of 2024 towards our goal of patient enrollment completion of our pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), which is expected in the first half of 2025,” said Shaun Bagai, CEO of RenovoRx. ...

What happened to renovorx?

LOS ALTOS, Calif., November 14, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023. ...

How much cash did renovocath have in 2024?

As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Operations to Achieve Next Interim Read-Out and Fund Current RenovoCath Commercialization Efforts ...

What did Tronox report in Q4 2024?

STAMFORD, Conn., Oct. 24, 2024 /PRNewswire/ — Tronox Holdings plc (NYSE:TROX) (“Tronox” or the “Company”), the world’s leading integrated manufacturer of titanium dioxide (“TiO 2 “) pigment, today reported its financial results for the quarter ending September 30, 2024, as follows: Third Quarter 2024 Financial Highlights: Q4 2024 Outlook: ...

Is renovorx a biopharmaceutical company?

LOS ALTOS, Calif., November 14, 2023 -- ( BUSINESS WIRE )-- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023. ...

What were the Financial Highlights for 3rd quarter ended September 30 2024?

Financial Highlights for Third Quarter ended September 30, 2024 (unaudited): Cash Position: Cash and cash equivalents as of September 30, 2024, were $9.6 million. R&D Expenses: Research and development expenses were approximately $1.7 million for the three months ended September 30, 2024, remaining flat compared to the same period last year. ...